Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 1—January 2023
Research

Risk for Severe COVID-19 Outcomes among Persons with Intellectual Disabilities, the Netherlands

Monique C.J. Koks-LeensenComments to Author , Bianca W.M. Schalk, Esther J. Bakker-van Gijssel, Aura Timen, Masha E. Nägele, Milou van den Bemd, Geraline L. Leusink, Maarten Cuypers, and Jenneken Naaldenberg
Author affiliations: Radboud Institute for Health Sciences, Nijmegen, the Netherlands (M.C.J. Koks-Leensen, B.W.M. Schalk, E.J. Bakker–van Gijssel, A. Timen, M.E. Nägele, M. van den Bemd, G.L. Leusink, M. Cuypers, J. Naaldenberg); Siza, Arnhem, the Netherlands (E.J. Bakker-van Gijssel); Maastricht University Medical Center, Maastricht, the Netherlands (G.L. Leusink)

Main Article

Table 1

Characteristics and outcomes for 2,586 persons included in a study of risk for severe COVID-19 outcomes among persons with intellectual disabilities, the Netherlands*

Characteristics Mild illness, n = 2,326 Severe illness, n = 161 Died, n = 99† Total, n = 2,586
Sex, no. (%), n = 2,525
M 1,315 (58.0) 103 (64.0) 58 (59.2) 1,476 (58.5)
F
951 (42.0)
58 (36.0)
40 (40.8)
1,049 (41.5)
Median age, y (IQR), n = 2,519
49 (32.0–61.0)
61 (52.0–67.5)
68 (61.0–76.0)
51 (34–62)
Age groups, no. (%), n = 2,519
0–17 y 81 (3.6) 0 1 (1.0) 82 (3.3)
18–39 y 721 (31.9) 16 (9.9) 2 (2.0) 739 (29.3)
40–49 y 330 (14.6) 16 (9.9) 4 (4.0) 350 (13.9)
50–59 y 491 (21.7) 44 (27.3) 16 (16.2) 551 (21.9)
60–69 y 399 (17.7) 57 (35.4) 32 (32.3) 488 (19.4)
>70 y
237 (10.5)
28 (17.4)
44 (44.4)
309 (12.3)
Long term care type, no. (%)
Group home 1,853 (79.7) 132 (82.0) 82 (82.8) 2,067 (79.9)
Independent living 349 (15.0) 28 (17.4) 16 (16.2) 393 (15.2)
Other or unknown
124 (5.3)
1 (0.6)
1 (1.0)
126 (4.9)
Disability level, no. (%), n = 2,468
Borderline to mild 632 (28.5) 49 (31.2) 18 (18.9) 699 (28.3)
Moderate 798 (36.0) 47 (29.9) 42 (44.2) 887 (35.9)
Severe to profound
786 (35.5)
61 (38.9)
35 (36.8)
882 (35.7)
Disability etiology, no. (%)
Down syndrome
141 (6.1)
20 (12.4)
15 (15.2)
176 (6.8)
No. concurrent conditions (%)
None reported 1,383 (59.5) 62 (38.5) 40 (40.4) 1,485 (57.4)
1 reported 650 (27.9) 54 (33.5) 31 (31.3) 735 (28.4)
>1 reported
293 (12.6)
45 (28.0)
28 (28.3)
366 (14.2)
Concurrent conditions, no. (%)
Diabetes 117 (5.0) 19 (11.8) 15 (15.2) 151 (5.8)
Hypertension 159 (6.8) 20 (12.4) 16 (16.2) 195 (7.5)
Heart disease 95 (4.1) 11 (6.8) 14 (14.1) 120 (4.6)
Lung disease; asthma, COPD, or both 57 (2.5) 13 (8.1) 9 (9.1) 79 (3.1)
Epilepsy 229 (9.8) 25 (15.5) 14 (14.1) 268 (10.4)
Overweight, body mass index >25 kg/m2 587 (25.2) 67 (41.6) 24 (24.2) 678 (26.2)

*All persons included in the study had intellectual disabilities and tested positive for SARS-CoV-2 by PCR. Category totals do not always add up to column totals because of missing responses; percentages are based on variable totals per category. COPD, chronic obstructive pulmonary disease; IQR, interquartile range. †Case-fatality ratio 3.8%.

Main Article

Page created: November 08, 2022
Page updated: December 21, 2022
Page reviewed: December 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external